Literature DB >> 9126606

Expression, purification, and characterization of a catalytically active human cytochrome P450 1A2:rat NADPH-cytochrome P450 reductase fusion protein.

A Parikh1, F P Guengerich.   

Abstract

An enzymatically active human cytochrome P450 (P450) 1A2:rat NADPH-P450 reductase fusion protein was purified and partially characterized following heterologous expression in Escherichia coli. A cDNA was engineered to include the coding sequence for human P450 1A2 at its 5' end (up to but not including the stop codon) fused in-frame to the coding sequence for a truncated (soluble) rat NADPH-P450 reductase at its 3' end via an oligonucleotide sequence encoding the hydrophilic dipeptide Ser-Thr. This fusion plasmid was expressed in E. coli and the recombinant protein was purified from the detergent-solubilized membrane fraction via sequential DEAE, ADP-agarose, and hydroxylapatite chromatographies. The purified protein has the spectral characteristics of human P450 1A2 and cytochrome c reduction activity comparable to rabbit NADPH-P450 reductase. The fusion protein catalyzed 7-ethoxyresorufin O-deethylation and phenacetin O-deethylation to appreciable levels in the presence of NADPH and phospholipid. While these activities were comparable to those of other such P450:NADPH-P450 reductase fusion proteins, they were lower than those of the system reconstituted from its individual hemoprotein and flavoprotein components. Nevertheless, the production of a functional, catalytically self-sufficient monooxygenase in E. coli enhances the prospect of using bacterial systems for production and characterization of human P450 drug metabolites as well as for biodegradation of chemicals in the environment.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9126606     DOI: 10.1006/prep.1997.0721

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  3 in total

1.  Drug metabolism by CYP2C8.3 is determined by substrate dependent interactions with cytochrome P450 reductase and cytochrome b5.

Authors:  Rüdiger Kaspera; Suresh B Naraharisetti; Eric A Evangelista; Kristin D Marciante; Bruce M Psaty; Rheem A Totah
Journal:  Biochem Pharmacol       Date:  2011-06-24       Impact factor: 5.858

2.  A tricistronic human adrenodoxin reductase-adrenodoxin-cytochrome P450 27A1 vector system for substrate hydroxylation in Escherichia coli.

Authors:  S Giovanna Salamanca-Pinzón; F Peter Guengerich
Journal:  Protein Expr Purif       Date:  2011-05-20       Impact factor: 1.650

3.  Engineering human cytochrome P450 enzymes into catalytically self-sufficient chimeras using molecular Lego.

Authors:  Vikash Rajnikant Dodhia; Andrea Fantuzzi; Gianfranco Gilardi
Journal:  J Biol Inorg Chem       Date:  2006-07-22       Impact factor: 3.358

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.